Elusys Therapeutics, Inc
Budget
€10 — €0
EP Access
0
accredited persons
Staff
2
0.2 FTE
EU Grants
None
Mission & Goals
Biodefense and health security preparedness and advocacy
EU Legislative Interests
Healthcare, health security, and biodefense related legislation
Communication Activities
No current communication activities, previous updates can be found here: https://elusys.com/news-media. Previously, held European Union - EMA marketing authorization for Obiltoxaximab, an Anthrax antitoxin, which included marketing, regulatory, and communications activities in Europe and with the European Union representatives about this product.
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
Biotechnology Innovation Organization
Organisation Members
No other EU memberships
Connected Legislation
Commissioner Meetings
No recorded meetings with EU commissioners.